Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A key hormone in the fetal liver has been found for the first time to play a critical role in determining iron endowment in the newborn baby. Up until now, widely held notions made in comparison to how the adult liver controls iron in the body have led to a common focus on how maternal iron status and function of the placenta determines a baby's iron status. A new study from the Lakhal-Littleton group reveals a more autonomous process takes place within the fetus than previously understood.

Samira's visual abstract for iron paper Blood June 2020

Historically, research into iron has focused on its role in the synthesis of haemoglobin, the substance in red blood cells that carries oxygen from your lungs throughout your body. However, in recent years evidence has been uncovered that iron plays an important role in many other physiological processes. For example, iron deficiency has been shown to impair cardiovascular function independently of haemoglobin levels in key Lakhal-Littleton lab papers in eLife and PNAS. In infancy, iron deficiency is associated with growth retardation and both motor skill and cognitive defects, because iron is required for the synthesis of myelin, an essential component of neurons, and also for rapid bone and muscle growth during childhood. While it is known that a liver-derived hormone called Hepcidin is responsible for regulating iron in the body, what is not well understood is the role it plays in the development of the unborn baby during pregnancy.

In the adult, it has been known for some time that hepcidin controls iron homeostasis by blocking the iron exporter ferroportin in the gut and spleen, which are sites of iron absorption and recycling respectively, thereby preventing iron from leaving these sites and being acquired into the bloodstream. Hepcidin is also present in the fetal liver, while ferroportin is found in abundance in the placenta, the organ where nutrients including iron are transferred from the mother to the fetus. Therefore, up until now, it has been widely accepted that the fetal liver controls iron availability to the fetus by operating in a similar manner to hepcidin in the adult liver; by blocking ferroportin in the placenta and thus preventing iron from being acquired into the mother’s circulation. This long-standing assumption heavily implies that fetal hepcidin is a negative regular of fetal iron levels.

A new paper from the Lakhal-Littleton lab has shown for the first time that fetal liver hepcidin does not control ferroportin in the placenta. Instead, the research reveals that fetal liver hepcidin acts cell-autonomously to block iron export out of fetal hepatocytes. This process enables the fetal liver to achieve rapid build-up of liver iron stores in the third trimester of gestation that is independent from both the iron status of the mother and from placental function. This key finding means that the fetal liver plays an active rather than passive role in determining iron endowment in the newborn. It can therefore be considered a positive regulator. 

According to lead researcher Associate Professor Samira Lakhal-Littleton: “The fundamental misunderstanding is that the levels of iron endowment in newborns are dependent on the transfer of maternal iron into the fetus across the placenta. The fetal liver was seen as a passive bystander in this process. As such, studies concerned with understanding the determinants of newborn iron endowment have focussed on maternal iron status and on placental function.”

Iron deficiency is very common amongst pregnant women because of the high demand for iron during the third trimester. The team’s results present important implications for the medical advice given to women during this stage of pregnancy. Prof Lakhal-Littleton said: “The decision as to whether to supplement these women with iron is based on their haemoglobin levels rather than on any measure relating to fetal iron status. The present study highlights the need to consider fetal iron levels in this process. This is not done currently because it is assumed that fetal iron status is entirely dependent on maternal iron status. Our study challenges that assumption.”

The team have also shown that this rapid accumulation of liver iron stores in the fetus supports the development of red blood cells, which at this stage occurs mainly in the fetal liver. Prof Lakhal-Littleton said: “It has been known for some time that fetal red blood cells develop in the fetal liver in late gestation. What was unclear, is how these developing red blood cells acquired the iron they need to make haemoglobin. What our study demonstrates is that iron stored in fetal liver cells acts as a supply of iron for developing red blood cells in the fetal liver.”

Liver iron endowment at birth is an important determinant of physical and neurological growth. This study ultimately shows that fetal liver hepcidin is essential for ensuring adequate iron endowment at birth.

“Up to now, clinicians have not been concerned with measuring fetal hepcidin. This can be done in cord blood. There is evidence that inflammatory conditions that occur during pregnancy affect maternal hepcidin levels, such as preeclampsia. What we need to understand is how fetal hepcidin is affected in these conditions, and whether changes in fetal hepcidin contribute to the developmental defects associated with such conditions.” (Prof Lakhal-Littleton).

The full paper, "Fetal liver hepcidin secures iron stores in utero" is available to read in "Blood".


Similar stories

Researcher publishes children's book of the brain

Postdoctoral Publication

Betina Ip, a Royal Society Dorothy Hodgkin Research Fellow based in NDCN, formerly a postdoctoral research scientist in DPAG, has written a book for children: The Usborne Book of the Brain

Drug trial that could improve respiratory recovery from COVID-19 now underway


A clinical trial has commenced this week to test whether a drug called almitrine can help people who are seriously ill with COVID-19 to recover from the disease.

Same genome, different worlds: How a similar brain causes sexually dimorphic behaviours

CNCB Goodwin Group News Publication Research

A new paper from the Goodwin group based in DPAG's Centre for Neural Circuits and Behaviour has shown how males and females are programmed differently in terms of sex.

New form of gift wrap drives male reproductive success

Publication Research Wilson Group News

The transfer of complex mixtures of signals and nutrients between individuals is a key step in several biologically important events in our lives, such as breastfeeding and sexual intercourse. However, we know relatively little about the ways in which the molecular gifts involved are packaged to ensure their successful delivery to the recipient.

Just over half of British Indians would take COVID vaccine

EDI News Outreach Postdoctoral Publication Research Riley Group News

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.